linaclotide (Rx)

Brand and Other Names:Linzess
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

capsule

  • 72mcg
  • 145mcg
  • 290mcg

Irritable Bowel Syndrome

Indicated for irritable bowel syndrome with constipation (IBS-C)

290 mcg PO qDay

Chronic Idiopathic Constipation

Indicated for chronic idiopathic constipation (CIC)

145 mcg PO qDay

72 mcg PO qDay may be used based on individual presentation

Dosage Modifications

Renal or hepatic impairment

  • Not expected to affect clearance of linaclotide or its active metabolite because linaclotide metabolism occurs within gastrointestinal tract and plasma concentrations are not measurable following administration of recommended dosage

<2 years: Contraindicated

<18 years: Safety and efficacy not established (see Black Box Warnings and Cautions)

Irritable Bowel Syndrome

Not studied

Chronic Idiopathic Constipation

Use caution, selecting a dose should reflect the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy in this patient population

Next:

Adverse Effects

>10%

IBS-C

  • Diarrhea (20%)

CIC

  • Diarrhea (16-22%)

1-10%

IBS-C

  • Abdominal pain (7%)
  • Flatulence (4%)
  • Headache (4%)
  • Viral gastroenteritis (3%)
  • Abdominal distension (2%)
  • Severe diarrhea (2%)
  • Defecation urgency (<2%)
  • Fecal incontinence (<2%)
  • Vomiting (<2%)
  • Gastroesophageal reflux disease (<2%)

CIC

  • Abdominal pain (7%)
  • Flatulence (6%)
  • Upper respiratory tract infection (5%)
  • Sinusitis (3%)
  • Abdominal distension (1-3%)
  • Defecation urgency (<2%)
  • Fecal incontinence (<2%)
  • Dyspepsia (<2%)
  • Viral gastroenteritis (<2%)

Postmarketing Reports

Hypersensitivity reactions: Anaphylaxis, angioedema, rash (including hives or urticaria)

Gastrointestinal reactions: Hematochezia, nausea, rectal hemorrhage

Previous
Next:

Warnings

Risk of serious dehydration in pediatric patients

Contraindicated in pediatric patients aged <2 years

In nonclinical studies in neonatal mice, oral administration of a single, clinically relevant adult dose of linaclotide caused deaths due to dehydration

Contraindications

Patients aged <2 years due to risk of serious dehydration

Known or suspected mechanical gastrointestinal obstruction

Cautions

Pediatric risk

  • Contraindicated in patients <2 years of age
  • In neonatal mice, fluid secretion increased because of GC-C agonism resulting in mortality within the first 24 hr due to dehydration
  • There was no age-dependent trend in GC-C intestinal expression in a clinical study of children 2 to <18 years of age; there are insufficient data available on GC-C intestinal expression in children aged <2 years to assess the risk of developing diarrhea and its potentially serious consequences in these patients
  • Safety and efficacy in patients aged <18 years not established

Diarrhea

  • Diarrhea was the most common adverse reaction in clinical trials
  • In postmarketing reports, severe diarrhea associated with dizziness, syncope, hypotension and electrolyte abnormalities (hypokalemia and hyponatremia) requiring hospitalization or IV fluid administration have been reported
  • If severe diarrhea occurs, suspend dosing and rehydrate
Previous
Next:

Pregnancy & Lactation

Pregnancy

Linaclotide and its active metabolite are negligibly absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure

Insufficient data available data on use in pregnant women to inform any drug-associated risk for major birth defects and miscarriage

Animal data

  • No effects on embryofetal development were observed with oral administration of linaclotide in rats and rabbits during organogenesis at doses much higher than the maximum recommended human dosage
  • Severe maternal toxicity associated with effects on fetal morphology were observed in mice

Lactation

Linaclotide and its active metabolite were not detected in the milk of lactating women; in adults, concentrations of linaclotide and its active metabolite were below the limit of quantitation in plasma following multiple doses of the drug

Maternal use of the drug is not expected to result in exposure to the drug or its active metabolite in breastfed infants; there is no information on effects on milk production; consider developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant from the drug or from the underlying maternal condition

No lactation studies in animals have been conducted

Unknown whether negligible systemic absorption of linaclotide by adults will result in a clinically relevant exposure to breastfed infants

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Guanylate cyclase C (GC-C) agonist; activation of GC-C located on the luminal surface of intestinal epithelial cells leads to increased cyclic guanosine monophosphate (cGMP), anion secretion, fluid secretion, and intestinal transit

Appears to work topically rather than systemically; elevation in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit

Absorption

Minimal systemic absorption

Concentrations of linaclotide and its active metabolite in plasma are below the limit of quantitation after oral doses of 145 mcg or 290 mcg

Metabolism

Metabolized within the GI tract to its principal, active metabolite by loss of the terminal tyrosine moiety

Both linaclotide and the metabolite are proteolytically degraded within the intestinal lumen to smaller peptides and naturally occurring amino acids

Elimination

Excretion: 3-5% feces (parent compound) and virtually 100% of active metabolite

Previous
Next:

Administration

Oral Administration

Take on an empty stomach at least 30 minutes before first meal of the day

Swallow capsule whole; do not chew or crush

Missed dose

  • Skip missed dose and take next dose at regular time; do not take 2 doses at the same time

Difficulty swallowing tablets

  • May sprinkle capsule contents on applesauce or in water; not tested in other soft foods or liquids
  • Administration in applesauce
    • Place 1 teaspoonful of applesauce at room temperature into a clean container
    • Open capsule
    • Sprinkle entire contents (beads) on applesauce
    • Consume entire contents immediately; do not chew beads; do not store applesauce-beads mixture for later use
  • Administration in water
    • Pour ~1 ounce (30 mL) of bottled water at room-temperature into clean cup
    • Open capsule
    • Sprinkle entire contents (beads) into water
    • Gently swirl beads and water for at least 20 sec
    • Swallow entire mixture of beads and water immediately
    • Add another 30 mL of water to any beads remaining in cup, swirl for 20 seconds, and swallow immediately
    • Do not store the bead-water mixture for later use
    • Note: Drug is coated on surface of the beads and will dissolve off the beads into water; beads will remain visible and will not dissolve; therefore, it is not necessary to consume all beads to deliver complete dose
  • Nasogastric or gastric feeding tube administration in water
    • Open capsule and empty the beads into clean container with 1 ounce (30 mL) of room-temperature bottled water
    • Mix by gently swirling beads for at least 20 sec
    • Draw-up beads and water mixture to an appropriately sized catheter-tipped syringe and apply rapid and steady pressure (10 mL/10 sec) to dispense syringe contents into the tube
    • After administering the bead-water mixture, flush nasogastric/gastric tube with a minimum of 10 mL of water
    • Note: It is not necessary to flush all the beads through to deliver complete dose

Storage

Store at 25ºC (77ºF); excursions permitted between 15-30ºC (59-86ºF)

Keep in the original container; do not subdivide or repackage

Protect from moisture

Do not remove desiccant from the container

Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
Linzess oral
-
72 mcg capsule
Linzess oral
-
290 mcg capsule
Linzess oral
-
145 mcg capsule

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.